MAP2K6(MKK6)
Sign in to save this workspaceUniProt P52564 · PDB · AlphaFold · Substrate: p38a (K53A) · Clone: full length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Encorafenib | 48.4% | 51.6% | 98.50 | 0.755 |
| 2 | Pirtobrutinib | 36.9% | 63.1% | 99.49 | 0.656 |
| 3 | Lenvatinib | 36.4% | 63.6% | 97.74 | 0.726 |
| 4 | Ibrutinib | 18.7% | 81.3% | 94.74 | 0.723 |
| 5 | Acalabrutinib | 17.6% | 82.4% | 99.50 | 0.670 |
| 6 | Ceritinib | 16.6% | 83.4% | 95.44 | 0.618 |
| 7 | Fedratinib | 16.4% | 83.6% | 96.21 | 0.576 |
| 8 | Crizotinib | 15.4% | 84.6% | 91.39 | 0.581 |
| 9 | Ponatinib | 15.0% | 85.0% | 78.23 | 0.534 |
| 10 | Pralsetinib | 14.5% | 85.5% | 93.43 | 0.643 |
| 11 | Lapatinib | 14.2% | 85.8% | 99.25 | 0.616 |
| 12 | Mobocertinib | 11.7% | 88.3% | 97.22 | 0.757 |
| 13 | Remibrutinib | 10.1% | 89.9% | 99.50 | 0.721 |
| 14 | Pemigatinib | 9.9% | 90.1% | 98.23 | 0.718 |
| 15 | Capmatinib | 9.4% | 90.6% | 99.75 | 0.582 |
| 16 | Pexidartinib | 9.0% | 91.0% | 99.49 | 0.631 |
| 17 | Trametinib | 8.4% | 91.6% | 99.50 | 0.718 |
| 18 | Lorlatinib | 8.1% | 91.9% | 97.24 | 0.694 |
| 19 | Gedatolisib | 8.1% | 91.9% | 99.75 | 0.611 |
| 20 | Netarsudil | 6.8% | 93.2% | 93.22 | 0.676 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 1.18
- Epithelial log2(TPM+1): 2.15
- Fold change: -0.96
- Status: No significant change
Selectivity landscape vs inhibition on MAP2K6
Each point is one of the 92 approved drugs; color = inhibition % on MAP2K6.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…